Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=24859229
&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215
Antibodies directed against receptor tyrosine kinases: current and future
strategies to fight cancer
#MMPMID24859229
Fauvel B
; Yasri A
MAbs
2014[Jul]; 6
(4
): 838-51
PMID24859229
show ga
Approximately 30 therapeutic monoclonal antibodies have already been approved for
cancers and inflammatory diseases, and monoclonal antibodies continue to be one
of the fastest growing classes of therapeutic molecules. Because aberrant
signaling by receptor tyrosine kinases (RTKs) is a commonly observed factor in
cancer, most of the subclasses of RTKs are being extensively studied as potential
targets for treating malignancies. The first two RTKs that have been targeted by
antibody therapy, with five currently marketed antibodies, are the growth factor
receptors EGFR and HER2. However, due to systemic side effects, refractory
patients and the development of drug resistance, these treatments are being
challenged by emerging therapeutics. This review examines current monoclonal
antibody therapies against RTKs. After an analysis of agents that have already
been approved, we present an analysis of antibodies in clinical development that
target RTKs. Finally, we highlight promising RTKs that are emerging as new
oncological targets for antibody-based therapy.
|*Neoplasms/drug therapy/enzymology
[MESH]
|Animals
[MESH]
|Antibodies, Monoclonal/*therapeutic use
[MESH]
|Drug Design
[MESH]
|Drug Resistance, Neoplasm/*drug effects
[MESH]
|ErbB Receptors/*therapeutic use
[MESH]
|Humans
[MESH]
|Protein Kinase Inhibitors/*therapeutic use
[MESH]
free
free
free
